Erlizumab

A4DAB110 | Phase-II

Target ITGB2/CD18

Isotype / Subclass G1 / None

Company

Genentech PDL Biopharma Roche

Clinical Status Phase-II

Format Whole mAb

Synonyms

—

pH Formulation —

IMGT PubChem (50069679) PubChem (135335294) PubChem (160709192) PubChem (472423143) PubChem (497387791) PubChem (497391296) PubChem (513904640) Thera-SAbDab YAbS

Avg A4D Score

-0.796

Score Range

-0.8

Structures

Avg. A4D Score per Structure

pH at Min / Max Aggregation Propensity

Structure ID	Source PDB	Seq. Identity	Avg. A4D Score	pH (Min Agg.)	pH (Max Agg.)	Score CDR	Score non-CDR
A4DAB110_2fgw_H_L	2fgw	100%	-0.796	6.5	4.0	-0.6872	-0.8248

Erlizumab

Avg. A4D Score per Structure

pH at Min / Max Aggregation Propensity

Associated Structural Profiles Level 2